Uveitis Drug Market in Global Industry: Demands, Insights, Research and Forecast

Posted by ojasdbmr on April 30th, 2021

Global uveitis drug market is rising gradually to an estimated value of USD 736.99million by 2026 registering a substantial CAGR of 7.2% in the forecast period of 2020-2026. Uveitis is the inflammatory diseases of the eye that produces swelling and damage the surrounding tissue of uvea, the middle layer of the eye that consist of choroid, ciliary body and iris. These diseases are not only limited to uvea but also affect the other eye parts like lens, retina and optic nerve producing slightly reduce vision or vision loss. A person with uveitis experiences blurred vision, dark, floating spots in the vision (floaters), eye pain, redness of the eye, sensitivity to light (photophobia) depending upon the type of inflammation.

Segmentation: Global Uveitis Drug Market

•          By Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis)
•          By Mechanism of Action Type (Corticosteroids, Immunomodulators, Calcineurin Inhibitors, Antimetabolites, Alkylating Agents, T-Cell Inhibitors, Anti-Microbials, NSAIDs, Intracameral Tissue Plasminogen Activator (TPA))
•          By Drug Type (Bethamethasone, Dexamethasone, Prednisolone, Cortisone, Methotrexate, Azathioprine, and Mycophenolate Mofetil, Bevacizumab, Tacrolimus, Cyclophosphamide, Adalimumab)
•          By Route of Administration (Topical, Oral, Intravenous, Subcutaneous, Intramuscular, Intravitreal and Others)
•          By End- Users (Hospitals, Homecare, Specialty Clinics, Drug Stores,  Others)

Download exclusive PDF sample report@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uveitis-drug-market

Key Market Players: Global Uveitis Drug Market

Few of the major competitors currently working in the global uveitis drug market are Xoma, Eye oint harmaceuticals, Novartis AG, Allergan, Enzo iochem Inc, Abbvie IncBausch & Lomb Pvt Ltd, Topivert Ltd, Santen harmaceutical Co., Ltd, Pfizer Inc, Johnson & Johnson Services, Inc,  Regeneron Pharmaceuticals, Inc, Hanall Biopharma, Daiichi sankyo company, limited, Alphamab Co. Ltd, Coherus BioSciences, Captisol, Clearside Biomedical, Eyegate, Eyevensys.

Competitive Analysis: Global Uveitis Drug Market

Global uveitis drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uveitis drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Drivers

•          The global uveitis drug market is witnessing substantial growth due to increased aging population
•          Growing prevalence of uveitis and related complications
•          Introduction of innovative biologics, fast-track approval of pipeline drugs, increasing research and development investments in drug discovery and development
•          Rising government initiatives to minimize eye disorders are also driving the growth of the global uveitis drug market
•          Introduction of new routes for drug administration that improves the efficiency of the drug
•          With the advancement of molecular biology, some intravitreal implants and biologic agents are increasingly used for the treatment of uveitis
•          By the development of molecular biology, more therapeutic agents and approaches have been applied to control ocular inflammation caused by uveitis, which are expected to have a positive influence on the uveitis drug market

Market Restraints

•          The adverse effects related to uveitis treatment medication such as watery eyes, irritation and other factors
•          Poor primary healthcare infrastructure
•          Lack of awareness about eye disorders and lack of health insurance in developing countries are also obstructing the uveitis treatment market